Emergent Biosolutions (NYSE:EBS) reported earnings of $1.07 per share beating Walls Streets expectations.

ME Staff
-
0

Emergent Biosolutions (NYSE:EBS) reported Q2 2018 earnings this Afternoon, coming in at $1.07 per share, beating Wall Street’s estimates of $0.89 per Share. Revenue for the quarter came in at $220.20 million beating analyst estimates of $208.94 million

Recent Insider Trading for Emergent Biosolutions (NYSE:EBS)

  • On 7/12/2018 Fuad El-Hibri, Chairman, sold 15,000 with an average share price of $54.50 per share and the total transaction amounting to $817,500.00.
  • On 7/9/2018 Fuad El-Hibri, Chairman, sold 15,000 with an average share price of $53.61 per share and the total transaction amounting to $804,150.00.
  • On 6/11/2018 George A Joulwan, Director, sold 5,000 with an average share price of $52.89 per share and the total transaction amounting to $264,450.00.
  • On 6/6/2018 Kathryn C Zoon, Director, sold 376 with an average share price of $52.81 per share and the total transaction amounting to $19,856.56.
  • On 6/5/2018 Daniel Abdun-Nabi, CEO, sold 15,785 with an average share price of $52.11 per share and the total transaction amounting to $822,556.35.
  • On 5/24/2018 Kathryn C Zoon, Director, sold 1,377 with an average share price of $51.15 per share and the total transaction amounting to $70,433.55.



    About Company
    Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

    Recent Analyst Rating for Emergent Biosolutions (NYSE:EBS)



      Recent Trading for Emergent Biosolutions (NYSE:EBS)
      Shares of Emergent Biosolutions closed the previous trading session at with shares trading hands.